Technical References ( EpiOral )
715. NUCLEOTIDE EXCISION REPAIR IS REDUCED IN ORAL EPITHELIAL TISSUES COMPARED WITH SKIN.
Mitchell1, D., Paniker1, L. and Godar2, D. 1Department of Carcinogenesis, University of Texas, MD Anderson Cancer Center, Smithville, TX. 2US Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, MD. Photochem. and Photobio., 88, 1027–1032, (2012).
683. UPDATE ON VALIDATION STATUS AND INDUSTRY UTILIZATION OF NORMAL HUMAN 3D (NHU-3D) ANIMAL ALTERNATIVE MODELS.
Kandarova, H., Klausner, M., Kubilus, J., Ayehunie, S., Hayden, P., Kaluzhny, Y., Letasiova, S., and Sheasgreen, J. MatTek Corporation, Ashland, MA, USA and MatTek In Vitro Life Science Laboratories, Bratislava, Slovakia. Presented at 8th World Congress on Alternative and Animal Use, Montreal, Canada, 2011.
672. RETENTION OF O-CYMEN-5-OL AND ZINC ON RECONSTRUCTED HUMAN GINGIVAL TISSUE FROM A TOOTHPASTE FORMULATION.
Yang, J., Deol, G. and Myangar, N. GlaxoSmithKline Consumer Healthcare, Weybridge, UK. Inter. Dental Journal, 61 (Suppl. 3): 41-45, 2011.
670. IN VITRO EFFECTS OF ETHANOL AND MOUTHRINSE ON PERMEABILITY IN AN ORAL BUCCAL MUCOSAL TISSUE CONSTRUCT.
Koschier1, F., Kostrubsky2, V., Toole3, C., Gallo4, M.A. 1Johnson & Johnson Consumer Products Company, Morris Plains, NJ 07950, United States, 2Vistakon, Division of Johnson & Johnson Vision Care, Jacksonville, FL 32256, United States, 3CeeTox, Inc., Kalamazoo, MI 49008, United States, 4UMDNJ – Robert Wood Johnson Medical School, Piscataway, NJ 08854, United States. Food Chem Toxicol., 49, 10, 2534-9, (2011).
667. EVALUATION OF TISSUE ENGINEERED MODELS OF THE ORAL MUCOSA TO INVESTIGATE ORAL CANDIDIASIS.
Yadev1, N.P., Murdoch1, C., Saville2, S.P., Thornhill1, M.H. 1Academic Unit of Oml & Maxillofacial Medicine & Surgery, School of Clinical Dentistry, University of Sheffield, Sheffield SIO 2TA, UK. 2Department of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, TX 78249, USA. Microbial Pathogenesis, 50, 278-285, (2011).
632. IDENTIFYING CELL AND MOLECULAR STRESS AFTER RADIATION IN A THREE-DIMENSIONAL (3-D) MODEL OF ORAL MUCOSITIS.
Lambros1, M.P., Parsa2, C., Mulamalla1, H.C., Orlando2, R., Lau4, B., Huang1,4, Y., Pon3, D., Chow3,4, M. 1Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, United States 2Department of Clinical Sciences, College of Osteopathic Medicine, Western University of Health Sciences, Pomona, CA 91766, United States 3Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, United States 4Center for Advancement of Drug Research and Evaluation (CADRE), Western University of Health Sciences, Pomona, CA 91766, United States. Biochem. And Biophys. Res. Comm., 405, 102-106 (2011).
621. GENOTOXICITY TESTING USING THE NORMAL HUMAN CELL BASED 3D EPITHELIAL MODELS.
Kaluzhny, Y., Karetsky, V., DeLuca, J., Armento, A., Hayden, P., Ayehunie, S. and Klausner, M. MatTek Corporation, Ashland, MA, USA. IIVS In Vitro Alternatives Forum, October 2010.
551. HIV TYPE 1 FAILS TO TRIGGER INNATE IMMUNE FACTOR SYNTHESIS IN DIFFERENTIATED ORAL EPITHELIUM.
Nittayananta1, W., Hladik2,3,4, F., Klausner5, M., Harb6, S., Dale3,7,8,9, B.A., and Coombs3,6, R.W. 1Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand. 2Departments of Obstetrics and Gynecology and 3Department of Medicine, University of Washington, Seattle, Washington 98104. 4Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109. 5MatTek Corporation, Ashland, Massachusetts 01721. 6Department of Laboratory Medicine, 7Department of Oral Biology, 8Department of Periodontics, and 9Department of Biochemistry, University of Washington, Seattle, Washington 98104. Aids Research And Human Retroviruses, 25, 10, 2009.
519. TRANSDERMAL AND BUCCAL DELIVERY OF METHYLXANTHINES THROUGH HUMAN TISSUE IN VITRO.
Thakur1, R.A., Michniak1, B.B., Meidan2, V.M. 1Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, 2Department of Pharmaceutical Sciences, University of Strathclyde, Glasgow, Scotland, UK. Drug Development and Industrial Pharmacy, 33, 513–521, (2007).
507. DEVELOPMENT OF AN EPIORAL IN VITRO HUMAN TISSUE MODEL FOR ORAL IRRITANCY TESTING.
Delves1, S.J., Faux1, S.P., Jai1, T.S., Kumaraveland1, T.S., Neilson2, L.R., and Meredith2, C. 1Toxicology Group, Advanced Technologies (Cambridge) Limited, 210 Cambridge Science Park, CB4 0WA, 2British American Tobacco, Group Research and Development, Southampton, SO15 8TL.
450. METHODS FOR ASSESSMENT OF PROLIFERATION IN AN IN VITRO TISSUE MODEL OF ORAL EPITHELIA.
Ackerman, G.L., Chlipata, E. Premier Laboratory, LLC, University of Colorado, Boulder, CO. Histologic, Vol. 38, No. 1, May 2005.
439. INFECTION OF HUMAN CYTOMEGALOVIRUS IN CULTURED HUMAN GINGIVAL TISSUE.
Hai, R., Chu, A., Li, H., Umamoto, S., Rider, P., and Liu, F. Program in Infectious Diseases and Immunity, Program in Comparative Biochemistry, School of Public Health, 140 Warren Hall, University of California, Berkeley, CA 94720, USA. Virology Journal, 3:84, (2006).
438. ORGANOTYPIC HUMAN ORAL TISSUE MODELS FOR TOXICOLOGICAL STUDIES.
Klausner1, M., Ayehunie1, S., Breyfogle1, B.A., Wertz2, P.W., Bacca3, L., Kubilus1, J. 1MatTek Corporation, Ashland, MA 01721, United States, 2University of Iowa, Iowa City, IA 52242, United States, 3Procter and Gamble Company, Mason, OH 45040, United States. Toxicology in Vitro, 21, 938-949 (2007).
429. A HUMAN ORAL TISSUE MODEL TO EVALUATE TOXICITY AND ANTI-HIV ACTIVITY OF THE SPERMICIDE-MICROBICIDE, NONOXYNOL-9M.
Chang1, M., Klausner2, M., Hladik3, F., Ayehunie2, S., Nittayananta4, W., Coombs1, R.W. 1Department of Laboratory Medicine, University of Washington, 4Department of Oral Biology, University of Washington, 3Program in Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, WA, 2MatTek Corporation, Ashland, MA. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, (2007).
424. ANTIMICROBIAL BARRIER OF AN IN VITRO ORAL EPITHELIAL MODEL.
Kimball1, J., Nittayananta1, W., Klausner4, M., Chung1, W., Dale1,2,3, B. 1Department of Oral Biology, University of Washington, 2Department of Medicine/Dermatology, University of Washington, 3Department of Biochemistry, University of Washington, 4The MatTek Corporation, Ashland, MA. Arch. Oral Biol., 51, 775-783 (2006).
399. CHARACTERIZATION AND TESTING OF NEW BUCCAL AND GINGIVAL TISSUE MODELS.
Kubilus1, J., Ayehunie1, S., Breyfogle1, B., Dale2, B., Kimball2, J., Wertz3, P., Klausner1, M. 1MatTek Corporation, Ashland, MA, USA; 2University of Washington, Seattle, USA; 3University of Iowa, Iowa City, USA. Poster presented at American Association for Dental Research and American Dental Education Association annual meeting, Orlando, FL, March 8-11 (2006).
395. BENZO[A]PYRENE-INDUCED ORAL CARCINOGENESIS AND CHEMOPREVENTION – STUDIES IN BIOENGINEERED HUMAN TISSUE.
Walle1, T., Walle1, U.K., Sedmera2, D., Klausner3, M. 1Department of Cell and Molecular Pharmacology and Experimental Therapeutics, University of South Carolina, Charleston; 2Department of Cell Biology and Anatomy, Medical University of South Carolina, Charleston; 3MatTek Corporation, Ashland, Massachusetts. Drug Metabolism and Disposition, 2006 34: 346-350.
386. EXPRESSION OF BETA-DEFENSINS IN RESPONSE TO HIV-1 IN AN ORAL TISSUE MODEL VS MONOLAYER CULTURES.
Nittayananta1, W., Hladik2, F., Klausner3, M., Harb1, S., Dale1, B.A., Coombs1, R.W. 1University of Washington; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3MatTek Corporation, Ashland, MA, United States. Presented at 10th European AIDS Conference/ EACS, Dublin, November 17-20, 2005.
379. EPIGINGIVAL™ (GIN-100) TISSUE MODELS FOR ORAL IRRITATION STUDIES.
Breyfogle1,B., Kubilus1, J., Dale2, B., Wertz3, P. 1MatTek Corporation, Ashland, MA, USA, 2University of Washington, Seattle, WA, USA, 3University of Iowa, Iowa City, IA, USA. Presented at 5th World Congress, Berlin, Germany, August, (2005).
363. DEVELOPMENT OF A HUMAN ORAL EPITHELIAL TISSUE MODEL TO STUDY HIV TRANSMISSION AND THE ROLE OF BETA-DEFENSINS.
Nittayananta1, W., Coombs1, R.W., Ayehunie2, S., Klausner2, M., Dale1, B.A. 1University of Washington, Seattle, WA; 2MatTek Corporation, Ashland, MA, United States. Presented at XV International AIDS Conference, Bangkok, Thailand, July 11-16, (2004).
360. NOVEL IN VITRO METHODOLOGY EVALUATING POTENTIAL MUCOSAL IRRITATION OF ORAL CARE FORMULATIONS.
Bacca, L.A., Jewell-Motz, E. A. Procter & Gamble Co., Mason, Ohio. Presented at the International Association of Dental Research Annual Meeting, Baltimore, MD, March 9-12, (2005).
325. CHARACTERIZATION OF NEW BUCCAL AND GINGIVAL EPITHELIAL TISSUE MODELS.
Kubilus1, J., Breyfogle1, B., Sheasgreen1, J., Hayden1, P., and Wertz2, P., Dale3, B., Kimball3, J., and Klausner1, M. 1MatTek Corporation, Ashland, MA, 2University of Iowa, Iowa City, IA, 3University of Washington, Seattle, WA. J. Invest. Dermatol., 122, (3), A79, Abstract #474, (2004).
292. HUMAN β-DEFENSIN EXPRESSION IN A NEW BUCCAL EPITHELIAL TISSUE MODEL.
Kubilus1, J., Breyfogle1, B., Sheasgreen1, J., Hayden1, P., Klausner1, M., Dale2, B.A., Kimball2, J.R. 1MatTek Corporation, Ashland, MA. 2University of Washington, Seattle, WA. J. Invest. Dermatol., 121, (1), Abstract #0045, (2003).
274. BARRIER FUNCTION COMPARISON BETWEEN IN VITRO SKIN, ORAL (BUCCAL), AND OCULAR TISSUE MODELS - IMPLICATIONS FOR DRUG DELIVERY STUDIES.
Klausner1, M., Kubilus1, J., Song2, Y., Michniak2, B., 1Department of Research and Development, MatTek, Ashland, MA, 2Department of Pharmacology and Physiology, UMDNJ-NJMS, Newark, NJ. Presented at the American Association of Pharmaceutical Scientists Meeting, November (2002).
263. GINGIVAL TISSUE MODEL FOR PREDICTION OF IRRITANCY OF ORAL CARE PRODUCTS.
Kubilus, J., Klausner, M., Breyfogle, B. MatTek Corporation, Ashland, MA. Presented at Soc. Invest. Derm. Meeting, May (2002).
www.MatTek.co.kr
